I can't believe this worked. But worked it did! Relief Therapeutics Holding AG (RLFTF) Other OTC - Other OTC Delayed Price. Currency in USD Add to watchlist 0.2470+0.0551 (+28.71%)<------------- At close: 3:59PM EDT
Ok, i took some time tonight to look into upcoming catalysts for IOVA and XAIR and typing them up here so I can keep them straight: IOVA. i looked into this on june 6, and at that time it seemed the melonoma (followed by cervical cancer) BLA's were shifted to the first half of 2022. a smaller event would be the release of the full cohort 4 data of the melanoma which they have held back as they deal with the FDA. Second quarter financial results conference call scheduled for Thursday, August 5, and maybe we can get revised dates then. Chardin has them as a buy with target of $51. XAIR. i never found a transcript for last week's investor presentation. people online seem to expect to hear from FDA august or september. in the xair quarterly report from 6/30, they said "we anticipate an FDA response towards the end of calendar 3Q 2021." Turns out this would have been a good buy this morning; it fell down to $6.06 at opening, and then recovered 9% to 6.60 by EOD.
TY janes. IOVA- There has been some light take out chatter! XAIR- I think my work was about a month advanced than the real timeline. FDA has been slow. Iridium Communications beats estimates, raises full-year service revenue growth outlook Jul. 20, 2021 7:05 AM ET Iridium Communications Inc. (IRDM)Iridium Communications Inc. (IRDM) Iridium Communications (NASDAQ:IRDM): Q2 GAAP EPS of $0.03 beats by $0.09. Revenue of $149.92M (+7.0% Y/Y) beats by $1.39M. Q2 Operational EBITDA was $94.78M vs. $85.26M in last year's quarter. Total billable subscribers grew 19% Y/Y, driving growth across all service categories. Increases full-year 2021 service revenue growth outlook to between 4% and 5% (+3% prior).
There is something about this SPAC that stands out. - I like ELMS! ... and now so does Dan Ives! Electric Last Mile Solutions lands bull rating from Wedbush on EV moat opportunity Jul. 20, 2021 7:26 AM ET Electric Last Mile Solutions, Inc. (ELMS) Wedbush Securities starts off coverage on Electric Last Mile Solutions (NASDAQ:ELMS) with an Outperform rating on what looks like a very favorable current climate for the company with the EV industry in the first inning of a $5T market opportunity over the next decade. Analyst Dan Ives says ELMS is building an EV moat in the commercial last mile by helping its customers save money by providing the lowest TCO possible. "The widespread shift to e-commerce seen across industries in buying and other fulfillment methods (buy online, pick up in-store, contactless delivery, etc.) has put last-mile delivery front and center with EV the next step on this last mile journey," notes Ives. Electric Last Mile Solutions is anticipated to have the first class 1 electric vehicle in the U.S. market with the Urban Delivery model. The firm assigns a price target of $17 to Electric Last Mile Solutions to rep more than 70% upside for shares. Electric Last Mile Solutions began trading on the Nasdaq on June 28 following the completion of the company’s previously announced business combination with SPAC Forum Merger III Corporation. I'm this close to just going full bore on these SPAC's I don't care any more. There are about three I really like, ELMS is one. Mattaport is one and....?
GBA has held ALLY through two threads- not easy. Ally Financial EPS beats by $0.83, beats on revenue Jul. 20, 2021 7:33 AM ETAlly Financial Inc. (ALLY)Ally Financial Inc. (ALLY) Ally Financial (NYSE:ALLY): Q2 Non-GAAP EPS of $2.33 beats by $0.83; GAAP EPS of $2.41 beats by $0.82. Revenue of $2.15B (+40.5% Y/Y) beats by $270M. Consumer auto originations of $12.9 billion, from a record 3.5 million decisioned applications. Insurance written premiums of $301 million | Highest 2Q consumer F&I written premiums | Lower incurred weather losses in 2Q. Retail deposits of $129.2 billion, up 12% YoY, and up $0.9 billion QoQ Shares +2% PM.
Turtle Bay Update. There has been drama with this holding. We have an outside agitator really giving the company hell. The co has made some mild changes but it looks like Turtle Beach hits session highs on report bidder Donerail prepared to `Go Nuclear'<---- BOOM! Jul. 19, 2021 3:53 PM ETTurtle Beach Corporation (HEAR)Turtle Beach Corporation (HEAR) Gaming headphone make Turtle Beach (NASDAQ:HEAR) hit session highs earlier, now up 4.1%, on a report that activist holder Donerail is prepared to go "nuclear" in its bid for the company. Donerail's bid was offer was described as a "first bid" that was fully financed, according to a CTFN report, which cited a person familiar. Donerail earlier today revealed it had a 4% stake in the company and that it made an offer that was at a "meaningful" premium that was rejected by Turtle Beach. After the disclosure, The Deal reported that the bid was in the mid $30s/share. Recall that CTFN reported in early May that the company hired bankers and was getting interest from potential buyers after a report that Donerail was pushing for a sale. !!!!!!!!!!!!!!!!!!
Motion Acquisition and DocGo indicate 175% growth in Q2 prelim revenue, raises FY outlook Jul. 20, 2021 7:44 AM ET Motion Acquisition Corp. (MOTN) Motion Acquisition (NASDAQ:MOTN) and its merger partner Ambulnz dba DocGo, provider of last-mile telehealth and integrated medical mobility services, announced that the latter has disclosed select prelim Q2 results. The quarter is highlighted by 175% Y/Y revenue growth to $61.9M, positive net income and positive adj. EBITDA performance. Mobile health revenue increased to more than $33M compared to $3.1M in year ago quarter; medical mobility revenue surged 47% to ~$28.6M. GAAP-basis net income stood at $0.1M compared to net loss of $1.7M in year ago quarter; adj. EBITDA stood at ~$2.9M compared to $0.2M. "While COVID-19 testing revenue subsided in the second quarter, we have successfully redeployed our resources across medical mobility and mobile health to generate long term growth. We are pleased to increase our full year revenue outlook to $170M (compared to its prior increased outlook for 2021 revenue of at least $160M) as a result," CEO of DocGo Stan Vashovsky.